Q3 EPS Forecast for Larimar Therapeutics Lifted by Analyst

Key Points

• Analysts at Wedbush have increased their Q3 2025 EPS forecast for Larimar Therapeutics from ($0.41) to ($0.33), maintaining an "Outperform" rating with a target price of $15.00.
• The company's latest earnings report showed a loss of ($0.41) per share, surpassing expectations of ($0.47).
• Insider activity is notable, with Director James E. Flynn acquiring 9,375,000 shares at an average price of $3.20, significantly increasing his stake in the company.

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Equities researchers at Wedbush boosted their Q3 2025 earnings per share (EPS) estimates for Larimar Therapeutics in a research note issued on Thursday, August 14th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.33) per share for the quarter, up from their prior estimate of ($0.41). Wedbush has a "Outperform" rating and a $15.00 price objective on the stock. The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share. Wedbush also issued estimates for Larimar Therapeutics' Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.53) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.44) EPS, FY2026 earnings at ($1.51) EPS, FY2027 earnings at ($1.21) EPS and FY2029 earnings at $2.76 EPS.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.06.

Other equities research analysts also recently issued research reports about the company. Citigroup restated a "buy" rating on shares of Larimar Therapeutics in a research report on Tuesday, June 24th. JMP Securities dropped their target price on Larimar Therapeutics from $22.00 to $18.00 and set a "market outperform" rating for the company in a research report on Friday. Finally, Guggenheim restated a "buy" rating and set a $26.00 target price on shares of Larimar Therapeutics in a research report on Tuesday, June 24th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $18.43.

Larimar Therapeutics Stock Down 5.9%

LRMR stock opened at $4.01 on Monday. The company has a market cap of $331.95 million, a P/E ratio of -2.57 and a beta of 0.93. Larimar Therapeutics has a twelve month low of $1.61 and a twelve month high of $9.50. The business has a fifty day moving average of $3.29 and a 200-day moving average of $2.77.

Institutional Investors Weigh In On Larimar Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets bought a new stake in Larimar Therapeutics in the fourth quarter valued at about $25,000. Algert Global LLC bought a new stake in shares of Larimar Therapeutics in the fourth quarter worth about $47,000. Savant Capital LLC bought a new stake in shares of Larimar Therapeutics in the second quarter worth about $39,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Larimar Therapeutics in the second quarter worth about $44,000. Finally, Graham Capital Management L.P. bought a new stake in shares of Larimar Therapeutics in the fourth quarter worth about $54,000. Institutional investors own 91.92% of the company's stock.

Insider Buying and Selling

In related news, Director James E. Flynn acquired 9,375,000 shares of the company's stock in a transaction that occurred on Thursday, July 31st. The stock was acquired at an average price of $3.20 per share, for a total transaction of $30,000,000.00. Following the completion of the acquisition, the director owned 9,538,945 shares of the company's stock, valued at $30,524,624. This trade represents a 5,718.38% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 4.50% of the company's stock.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.